Elanco Animal Health (NYSE:ELAN) Issues Q1 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) issued an update on its first quarter earnings guidance on Tuesday morning. The company provided earnings per share guidance of $0.29-$0.34 for the period, compared to the consensus earnings per share estimate of $0.30. The company issued revenue guidance of $1.155-$1.180 billion, compared to the consensus revenue estimate of $1.21 billion. Elanco Animal Health also updated its FY 2025 guidance to 0.800-0.860 EPS.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Barclays upped their price objective on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 8th. Morgan Stanley reduced their price objective on shares of Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 29th. Leerink Partners initiated coverage on shares of Elanco Animal Health in a report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 target price on the stock. Stifel Nicolaus reduced their target price on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a report on Friday. Finally, UBS Group began coverage on Elanco Animal Health in a report on Monday, December 9th. They issued a “buy” rating and a $18.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $16.00.

Elanco Animal Health Trading Down 5.4 %

Shares of NYSE:ELAN traded down $0.60 during mid-day trading on Tuesday, hitting $10.51. The stock had a trading volume of 4,621,139 shares, compared to its average volume of 4,672,827. The company’s 50 day moving average is $11.78 and its 200-day moving average is $13.09. Elanco Animal Health has a 12-month low of $10.20 and a 12-month high of $18.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The company has a market cap of $5.20 billion, a PE ratio of 26.28, a P/E/G ratio of 2.50 and a beta of 1.42.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same quarter in the previous year, the company earned $0.08 EPS. Elanco Animal Health’s revenue for the quarter was down 1.4% on a year-over-year basis. On average, sell-side analysts predict that Elanco Animal Health will post 0.91 EPS for the current year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.